FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Bid/Ask 18:48:13 26/06/2024 BST | ||
| 2.43 EUR | +0.41% |
|
| Current month | -35.64% | ||
| 1 month | -37.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 2.43 | +0.41% |
| 25/06/24 | 2.42 | +3.42% |
| 24/06/24 | 2.34 | -10.00% |
| 21/06/24 | 2.6 | +1.56% |
| 20/06/24 | 2.56 | -6.57% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 06:48 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2J1X |
| ISIN | DE000JK2J1X3 |
| Date issued | 23/02/2024 |
| Strike | 534.3 $ |
| Maturity | Unlimited |
| Parity | 24.9 : 1 |
| Emission price | 10.11 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.71 € |
|---|---|
| Lowest since issue | 2.03 € |
| Spread | 0.01 € |
| Spread % | 0.41% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
